Parvovirus vectors: use and optimisation in cancer gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Cancer incidence and mortality necessitate novel therapeutic strategies.
• Gene therapy presents a promising avenue for cancer treatment.
• Current gene delivery vectors face challenges like low efficiency and immunogenicity.

Purpose of the Study:

• To evaluate the potential of Parvoviridae family viruses as vectors for cancer gene therapy.
• To highlight the advantages of using these viruses compared to existing methods.

Main Methods:

• Review of existing literature on Parvoviridae viruses and gene therapy.
• Analysis of viral vector characteristics, including oncotropism, oncosuppression, and safety profiles.
• Comparison of Parvoviridae-based vectors with current viral and nonviral gene delivery systems.

Main Results:

• Parvoviridae viruses exhibit desirable traits for gene therapy, including tumor-specific targeting (oncotropism).
• These viruses demonstrate cancer-suppressing properties (oncosuppression) and enable long-term gene expression.
• They are characterized by a lack of pathogenicity in humans (apathogenicity), addressing safety concerns.

Conclusions:

• Viruses from the Parvoviridae family represent a potentially advantageous platform for developing novel cancer gene therapies.
• Their unique biological properties warrant further investigation for clinical applications in oncology.